Berberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide

被引:81
作者
Lin, Tseng-Hsi [2 ,3 ]
Kuo, Hsing-Chun [2 ,4 ]
Chou, Fen-Pi [2 ]
Lu, Fung-Jou [1 ]
机构
[1] Chung Shan Med Univ, Sch Appl Chem, Taichung, Taiwan
[2] Chung Shan Med Univ, Inst Biochem & Biotechnol, Taichung 402, Taiwan
[3] Taichung Vet Gen Hosp, Div Hematol, Dept Internal Med, Taichung, Taiwan
[4] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Med Res, Kaohsiung 833, Taiwan
关键词
D O I
10.1186/1471-2407-8-58
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Arsenic trioxide (As2O3) exhibits promising anticarcinogenic activity in acute promyelocytic leukemic patients and induces apoptosis in various tumor cells in vitro. Here, we investigated the effect of the natural alkaloid berberine on As2O3-mediated inhibition of cancer cell migration using rat and human glioma cell lines. Methods: The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was used to determine the viability of rat C6 and human U-87 glioma cells after treatment with As2O3 or berberine, and after co-treatment with As2O3 and berberine. The wound scratch and Boyden chamber assays were applied to determine the effect of As2O3 and berberine on the migration capacity and invasiveness of glioma cancer cells. Zymography and Western blot analyses provided information on the effect of As2O3 and berberine on the intracellular translocation and activation of protein kinase C (PKC), and some PKC-related downstream factors. Most assays were performed three times, independently, and data were analyzed using ANOVA. Results: The cell viability studies demonstrated that berberine enhances As2O3-mediated inhibition of glioma cell growth after 24 h incubation. Untreated control cells formed a confluent layer, the formation of which was inhibited upon incubation with 5 mu M As2O3. The latter effect was even more pronounced in the presence of 10 mu M berberine. The As2O3-mediated reduction in motility and invasion of glioma cells was enhanced upon co-treatment with berberine. Furthermore, it has been reported that PKC isoforms influence the morphology of the actin cytoskeleton, as well as the activation of metalloproteases MTI-MMP and MMP-2, reported to be involved in cancer cell migration. Treatment of glioma cells with As2O3 and berberine significantly decreased the activation of PKC a and e and led to actin cytoskeleton rearrangements. The levels of two downstream transcription factors, myc and jun, and MTI-MMP and MMP-2 were also significantly reduced. Conclusion: Upon co-treatment of glioma cells with As2O3 and berberine, cancer cell metastasis can be significantly inhibited, most likely by blocking the PKC-mediated signaling pathway involved in cancer cell migration. This study is potentially interesting for the development of novel chemotherapeutic approaches in the treatment of malignant gliomas and cancer development in general.
引用
收藏
页数:15
相关论文
共 62 条
[1]   Arsenic-induced apoptosis in malignant cells in vitro [J].
Akao, Y ;
Yamada, H ;
Nakagawa, Y .
LEUKEMIA & LYMPHOMA, 2000, 37 (1-2) :53-+
[2]   Inhibition of chemical carcinogenesis by berberine in rats and mice [J].
Anis, KV ;
Rajeshkumar, NV ;
Kuttan, R .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2001, 53 (05) :763-768
[3]  
Assert R, 1999, INT J CANCER, V80, P47, DOI 10.1002/(SICI)1097-0215(19990105)80:1<47::AID-IJC10>3.3.CO
[4]  
2-A
[5]   Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia [J].
Au, WY ;
Tam, S ;
Fong, BM ;
Kwong, YL .
BLOOD, 2006, 107 (07) :3012-3013
[6]   Cell transformation, invasion, and angiogenesis: A regulatory role for ornithine decarboxylase and polyamines? [J].
Auvinen, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (08) :533-537
[7]   Arsenic trioxide: Acute promyelocytic leukemia and beyond [J].
Bachleitner-Hofmann, T ;
Kees, M ;
Gisslinger, H .
LEUKEMIA & LYMPHOMA, 2002, 43 (08) :1535-1540
[8]   DIFFERENTIATED RAT GLIAL CELL STRAIN IN TISSUE CULTURE [J].
BENDA, P ;
LIGHTBODY, J ;
SATO, G ;
LEVINE, L ;
SWEET, W .
SCIENCE, 1968, 161 (3839) :370-+
[9]   Arsenic compounds in the treatment of multiple myeloma: A new role for a historical remedy [J].
Berenson, James R. ;
Yeh, Howard S. .
CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (03) :192-198
[10]   Apoptosis induction by arsenic: mechanisms of action and possible clinical applications for treating therapy-resistant cancers [J].
Bode, A ;
Dong, ZG .
DRUG RESISTANCE UPDATES, 2000, 3 (01) :21-29